目的 探讨艾迪注射液联合甲地孕酮治疗子宫内膜癌的临床效果。方法 选取选取2016年1月—2017年12月温县人民医院收治的68例子宫内膜癌患者，随机分为对照组和治疗组，每组各34例。对照组口服醋酸甲地孕酮片，160 mg/次，1次/d。治疗组在对照组治疗基础上静脉滴注艾迪注射液，50 mL加入450 mL生理盐水均匀混合后给药，1次/d，每个化疗周期连用14 d。两组均以21 d为1个周期，连续治疗3个化疗周期。观察两组的临床疗效，比较两组病灶最大直径、日进食量、体质量、KPS评分、人附睾蛋白4（HE4）、癌胚抗原（CEA）、糖类抗原125（CA125）、外周血辅助性T细胞（Th）1与Th2比值（Th1/Th2）、CD3⁺、CD4⁺/CD8⁺的变化情况。结果 治疗后，治疗组客观缓解率和临床获益率分别为64.7%、91.2%，显著高于对照组的38.2%、70.6%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组病灶最大直径较治疗前均显著缩小，日进食量、体质量及KPS评分均显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组病灶最大直径显著小于对照组，日进食量、体质量及KPS评分显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清HE4、CEA、CA125较治疗前均显著降低，Th1/Th2、CD3⁺、CD4⁺/CD8⁺较治疗前均显著增高，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组HE4、CEA、CA125水平显著低于对照组，Th1/Th2、CD3⁺、CD4⁺/CD8⁺显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗组骨髓抑制、脱发、消化道反应、肝肾功能异常、心功能异常毒副反应发生率均显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 艾迪注射液联合甲地孕酮治疗子宫内膜癌具有较好的临床疗效，能明显抑制肿瘤生长，改善患者生活状态，增强免疫功能，增效减毒优势显著，具有一定的临床推广应用价值。

Objective To investigate the clinical effects of Aidi Injection combined with megestrol in treatment of endometrial cancer. Methods Patients (68 cases) with endometrial cancer in Wen County People's Hospital from January 2016 to December 2017 were randomly divided into control (34 cases) and treatment (34 cases) groups. Patients in the control group were po administered with Megestrol Acetate Tablets, 160 mg/time, once daily. Patients in the treatment group were iv administered with Aidi Injection on the basis of the control group, 50 mL was added to 450 mL normal saline, once daily, and for 14 d in each chemotherapy cycle. 21 Days were as one cycle, and two groups were treated for 3 chemotherapy cycles. After treatment, the clinical efficacy was evaluated, and maximum diameter of the lesion, daily food intake, body quality, KPS score, HE4, CEA, CA125, Th1/Th2, CD3⁺, and CD4⁺/CD8⁺ in two groups before and after treatment were compared. Results After treatment, the objective remission rate and clinical benefit rate in the treatment group was 64.7% and 91.2%, which were significantly higher than 38.2% and 70.6% in the control group, and there were differences between two groups (P < 0.05). After treatment, maximum diameter of the lesion was significantly reduced, but daily food intake, body quality, and KPS score were significantly increased, and there were differences in the same group (P < 0.05). After treatment, the maximum diameter of the lesion in the treatment group was lower than that in the control group, but daily food intake, body quality, and KPS score were higher than those in the control group, and there were differences between two groups (P < 0.05). After treatment, HE4, CEA, and CA125 were significantly decreased in two groups, Th1/Th2, CD3⁺, and CD4⁺/CD8⁺ were significantly increased, and there were differences in the same group (P < 0.05). After treatment, HE4, CEA, and CA125 in the treatment group were lower than those in the control group, but Th1/Th2, CD3⁺, and CD4⁺/CD8⁺ were higher than those in the control group, and there were differences between two groups (P < 0.05). The incidence rates of bone marrow inhibition, hair loss, digestive tract reaction, liver and kidney abnormal function, and heart abnormal function in the treatment group were significantly lower than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Aidi Injection combined with megestrol has significant clinical effect in treatment of endometrial cancer, and can significantly inhibit tumor growth, also can improve living conditions and enhance immune function, and can increase efficiency and reduce toxicity, which has a certain clinical application value.